NEWS & MEDIA

Nov 10, 2026

The market leader in minimally invasive chronic rhinitis treatment is advancing therapies at the intersection of ENT and neurology.

Oct 06, 2026

Leading ENT-focused group purchasing organization confirms Aerin's minimally invasive RF technology as its preferred solution for chronic rhinitis and nasal airway obstruction.

April 2, 2026

Even after successful sinus surgery, many CRS patients continue to experience persistent rhinorrhea, often driven by an overlooked chronic rhinitis component. By using structured symptom assessment and targeted questioning, physicians can better identify these patients and address both conditions concurrently.

April 2, 2026

In sleep medicine, nasal airway obstruction (NAO) is often an overlooked barrier to therapy success, undermining both CPAP and oral appliance effectiveness. By incorporating routine nasal evaluation and collaborating closely with dental sleep specialists, ENTs can identify and address NAO earlier in the care pathway.

Mar 25, 2026

Milestone reflects growing adoption and reinforces the company’s mission to expand access to meaningful relief for patients suffering from chronic ENT conditions

January 7, 2026

In patients undergoing drug-induced sleep endoscopy (DISE), nasal airway obstruction is a common but often unaddressed contributor to sleep-disordered breathing. By incorporating VivAer® at the time of DISE, physicians can address nasal airflow during the same encounter, introducing a therapeutic opportunity without altering downstream treatment pathways.

January 6, 2026

In RhinAer, a temperature- and impedance-controlled RF therapy, temperature leads while impedance follows. Temperature and treatment time govern the desired biological effects and tissue response, whereas impedance reflects tissue apposition once energy has been delivered.

Oct 23, 2025

The temperature-and impedance-controlled radiofrequency RhinAer+ device treats the posterior nasal nerve (PNN) and comprehensively targets multiple anatomic contributors to chronic rhinitis, a chronic condition with substantial adverse health impact, along with sleep quality and worker productivity consequences.

September 4, 2025

This publication, together with Cigna Healthcare’s recent decision to cover RhinAer treatment of the PNN (CPT 31242) effective September 15, 2025, reinforces the growing recognition of RhinAer’s clinical efficacy and net health benefit as a minimally invasive alternative to surgery or long-term clinic-based management.

August 26, 2025

Dr. Scott Fortune and Dr. Michael Yim emphasizes how the recent Cigna coverage decision for RhinAer is not only a policy milestone, but also a call-to-action for physicians. Years of clinical advocacy and data have helped pave the way for 15 million more patients to have access to treatment. However, coverage does not equal care.

July 31, 2025

Dr. Chris Davis discusses how insurance limitations can impact access to care and highlights the role of self-pay options in expanding treatment availability. He encourages clear and early conversations about cost, focusing on expected health outcomes. His practice uses transparent pricing and payment plans to help patients understand their financial options.

Jul 22, 2025

We’re proud to announce the appointment of Lucas Buchanan to Aerin Medical’s Board of Directors. Mr. Buchanan is a seasoned MedTech leader with 25+ years of experience and brings deep expertise in commercialization, operations and finance.

June 27, 2025

Starting September 15, over 15 million Cigna members and their healthcare providers will gain access to this clinically proven solution for patients with chronic rhinitis, a persistent inflammatory condition that significantly compromises quality-of-life. Cigna’s policy update highlights the growing recognition of RhinAer’s clinical efficacy and net health benefit as a non-invasive alternative to surgery or long-term, ineffective medication and clinic-based management.

May 14, 2025

Following Recently Published VATRAC 3-Year RCT, New Findings Reinforce Consistent, Durable Benefits of Temperature-Controlled Radiofrequency (TCRF) Ablation for Nasal Airway Obstruction (NAO)

April 22, 2025

Positive 24-month results from RHINTRAC, a randomized, sham-controlled clinical trial, in the International Forum of Allergy & Rhinology (IFAR). These results demonstrate the durable treatment effect of RhinAer® for treating chronic rhinitis, showing a significant improvement in symptoms through two years. These findings build on the previously published results of two separate studies that also demonstrated significant, sustained improvement with RhinAer treatment.

April 2, 2025

The three-year results from the VATRAC Study confirm long-term efficacy of the VivAer® treatment, demonstrating sustained symptom relief, improved sleep, enhanced quality of life, and reduced medication burden.

March 31, 2025

Dr. Gavin Setzen, of Albany ENT and Allergy Services, highlights the critical role of NAO treatment in optimizing OSA care and navigating reimbursement to ensure patient access.

January 13, 2025

New equity capital positions Aerin Medical to drive additional commercial growth, advance market-leading innovation, and further expand its robust clinical evidence portfolio. The $32.5 million equity financing was led by all of Aerin's major investors: KCK MedTech, Questa Capital, OrbiMed, and Ally Bridge Group, with new participation by Ares Management Credit funds, which also provided Aerin a debt facility to refinance its existing debt and access additional capital.

September 9, 2024

Aerin Medical will showcase our innovative solutions at the upcoming ENT fall conferences in Miami. Don’t miss the chance to connect, learn, and discover how we are expanding access to meaningful relief for patients suffering from chronic ENT conditions.

May 10, 2024

Under the guidance of Dr. Meha Fox, a dedicated team of otolaryngology residents at the Michael E. DeBakey Veterans Affairs Medical Center in Houston is spearheading a transformative approach to treating chronic nasal conditions leveraging VivAer® and RhinAer®.

February 29, 2024

Positive 24-month results from RHINTRAC, a randomized, sham-controlled clinical trial, in the International Forum of Allergy & Rhinology (IFAR). These results demonstrate the durable treatment effect of RhinAer® for treating chronic rhinitis, showing a significant improvement in symptoms through two years. These findings build on the previously published results of two separate studies that also demonstrated significant, sustained improvement with RhinAer treatment.

February 8, 2024

Positive two-year outcomes from the VATRAC trial has been published in the Rhinology Journal. The study showed a single in-office treatment with VivAer® resulted in sustained improvement in symptoms of nasal airway obstruction (NAO) caused by nasal valve collapse, and reduced both daytime sleepiness and the use of medications and mechanical aids.

December 5, 2023

Two-year results of the RELIEF clinical trial published in The Laryngoscope confirm that a single procedure with RhinAer® resulted in sustained improvements in chronic rhinitis symptoms and quality of life, along with a substantial decrease in chronic rhinitis medication usage. RhinAer, a non-invasive technology developed by Aerin Medical Inc., uses temperature-controlled radiofrequency energy to provide relief from chronic rhinitis.

November 20, 2023

Derrick Sung has been appointed chief financial officer of Aerin Medical. Sung brings over 25 years of finance, capital market, and strategy experience across diverse roles within the medical device industry. Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation where he scaled the finance organization and led the company through significant growth and a successful IPO.

November 3, 2023

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that the Centers for Medicare and Medicaid Services (CMS) assigned payment for a new Category I Current Procedural Terminology (CPT®) code for endoscopic destruction of the posterior nasal nerve (PNN) using radiofrequency ablation.

October 18, 2023

VivAer® and RhinAer® were featured on BabyBoomers.com, an online resource for those embracing their golden years. In the article, Dr. Roheen Raithatha, FACS, FARS, discussed the changes in nasal anatomy and function that accompany aging, highlighting solutions available to address resulting chronic nasal conditions.

August 29, 2023

Aerin Medical co-founders, Scott Wolf, MD, and Andrew Frazier, reflect on the milestone achievement of 100,000 patients treated and share what’s next for the company. 

July 13, 2023

 Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced the publication of positive two-year follow-up data from the AERWAY trial for patients with severe or extreme nasal airway obstruction (NAO) due to nasal valve collapse (NVC)

April 18, 2023

Aerin Medical supports the recent American Academy of Otolaryngology-Head and Neck Surgery position statement. The statement recognizes nasal valve repair as “a distinct surgical procedure that can improve nasal obstruction symptoms for appropriately selected patients.”

January 23, 2023

VivAer® was recently featured in key news publications such as the San Francisco Chronicle, the Houston Chronicle, the Miami Herald, and more, following a patient testimonial campaign that reached millions of Americans.

January 2, 2023

VivAer® was featured in Woman’s World Magazine, a popular print publication reaching over one million Americans. The full-page article highlighted the story of Diana, a VivAer patient whose inability to breathe through her nose left her exhausted throughout the day.

November 16, 2022

CMS is set to implement a new CPT code that includes the use of VivAer to repair nasal valve collapse in the office and outpatient surgical settings. The new code goes into effect on January 1, 2023. VivAer is a non-invasive, temperature-controlled radiofrequency technology that provides long-term relief from nasal obstruction.

October 18, 2022

The American Medical Association (AMA) Current Procedural Terminology (CPT®) Editorial Panel accepted the application for a new Category I CPT code to report endoscopic destruction of the posterior nasal nerve using radiofrequency (RF) ablation...

Oct 11, 2022

We spoke with Dr. Randall A. Ow regarding his experience with RhinAer. We discussed why he adopted RhinAer into his practice, how he incorporated the treatment into his practice and how it has changed the way he treats his patients.

October 11, 2022

VivAer® was featured in a BackTable ENT podcast discussing in-office procedures for nasal valve obstruction. The podcast, featuring Dr. Mary Ashmead of Texas Ear, Nose, & Throat Specialists, was developed as a resource for otolaryngologists to learn tips, techniques, and practical advice on patient selection, treatment planning, and more.

September 8, 2022

Stylus now launching in the U.S. at American Rhinologic Society (ARS) and American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNSF) annual meetings...

September 6, 2022

Twelve-month active treatment group outcomes from the VATRAC trial published in JAMA Otolaryngology – Head & Neck Surgery confirm that treatment with VivAer® resulted in a reduction in nasal obstruction symptoms with durable improvement through 12 months. VivAer uses temperature-controlled radiofrequency energy to provide long-term relief from nasal obstruction.

Aug 12, 2022

RhinAer®, the comprehensive, non-invasive solution for chronic rhinitis, was recently featured in specialty clinical news outlet, Healio. The article highlighted the results of the RHINTRAC randomized controlled trial published in International Forum of Allergy & Rhinology,...

Jul 20, 2022

RhinAer®, the comprehensive, office-friendly solution for chronic rhinitis, was recently featured in specialty clinical news outlet, Healio...

Jul 19, 2022

We spoke with Dr. V. Vasu Kakarlapudi, primary investigator of the published 2-year pivotal RhinAer study. We discussed the common frustrations experienced by many of his chronic rhinitis patients, why he chooses RhinAer for his patients, and key implications of the new RhinAer study results.

July 19, 2022

Largest study of RhinAer to date shows 87% of patients reported quality-of-life improvements...

July 15, 2022

VivAer® was featured in Dental Sleep Practice Magazine. The article, titled “Nasal Airway Obstruction and Precision Oral Appliance Therapy in the Treatment of OSA”, discussed the connection between nasal airway obstruction (NAO) and sleep disordered breathing as well as the importance of treating NAO before oral appliance therapy is used in the treatment of obstructive sleep apnea (OSA).

July 6, 2022

Follow-up results from the trial’s active treatment arm showed that chronic rhinitis symptoms continued to improve ...

June 29, 2022

Long term follow-up published in International Forum of Allergy & Rhinology demonstrates...

June 16, 2022

Ally Bridge Group joins existing syndicate of KCK MedTech, Questa Capital and OrbiMed...

June 7, 2022

RhinAer treatment resulted in significant symptom improvement through 24 months in both non-allergic and allergic rhinitis patients...

Jun 06, 2022

RhinAer was featured on ABC-affiliate SoFlo Health TV as the “innovative new procedure you won’t want to miss.” In the interview, Dr. Jay Young, M.D., explained...

Feb 01, 2022

Aerin Medical founder, Scott Wolf, MD was featured in an exclusive founder interview series by The Tech Tribune...

Jan 18, 2022

More and more nasal airway procedures are moving from the operating room to an office setting. “Some of the main drivers of this change have been patient convenience, recovery time, and cost”, says Dr. Stanley McClurg, MD, FARS of ENT Associates in Kansas City, MO...

Jan 06, 2022

We are honored to announce that Aerin Medical was named one of the best tech startups in Sunnyvale by The Tech Tribune ...

Dec 15, 2021

Dr. Raj P. TerKonda, M.D., FACS, explains nasal airway obstruction and who may be a good candidate for treatment with VivAer ...

Oct 07, 2021

Congratulations to Stacey Silvers, MD, Jon Rosenthal, DO, Chad McDuffie, MD, David Yen, MD, and Joseph Han, MD. This team was recognized by the American Rhinologic Society ...

September 27, 2021

Results of Two Clinical Trials Evaluating Safety, Efficacy of VivAer® for Nasal Obstruction Patients with Nasal Valve Collapse to be Presented ...

September 13, 2021

Treatment with RhinAer resulted in significant symptom burden reduction, superior to sham control ...

Aug 16, 2021

RhinAer provided significant and lasting improvement in common chronic rhinitis symptoms, such as postnasal drip, congestion, nasal itching and persistent runny nose ...

Aug 05, 2021

Study adds to a growing body of clinical evidence supporting the safety and efficacy of VivAer, a non-invasive, temperature-controlled radiofrequency device ...

Jul 13, 2021

Treatment with VivAer, a non-invasive, temperature-controlled, radiofrequency (RF) device, resulted in significant symptom relief, superior to sham control ...

May 11, 2021

Matt Brokaw recently marked his one-year anniversary as CEO of Aerin Medical. To recognize the milestone, Matt sat down to answer some questions and share his reflections on the past year. ...

May 06, 2021

We are honored to announce that MedTech Breakthrough has named Aerin Medical the winner in the 2021 MedTech Breakthrough Awards program, taking home the “Best New Therapeutic Solution” award for RhinAer, our innovative treatment for chronic rhinitis. ...

Apr 21, 2021

Data shows in-office treatment of nasal valve collapse resulted in lasting improvement in symptoms and quality of life ...

Aug 17, 2020

Aerin Medical, a privately held medical device company focused on non-invasive procedures for treating nasal airway conditions, today announced the closing of a $48 million equity financing. ...

Aug 17, 2020

Aerosol-generating medical procedures present potential risk to practitioners, particularly during the SARS CoV-2 (COVID-19) pandemic. Particles

Aug 17, 2020

Chronic nasal obstruction contributes to a decreased quality of life. Nasal valve dysfunction is increasingly recognized as a cause of nasal obstruction ...

Mar 06, 2020

RhinAer™ Procedure Promises Lasting Relief for Millions of Americans Suffering from Common Chronic Condition ...

May 06, 2019

Judging by all the ads for things from nasal strips to sprays to medications, there are a lot of people who have trouble breathing ...

Feb 13, 2019

Tim Carr, a firefighter in Culver City, had tried lots of remedies for his blocked nasal airways. “I’ve gone through allergy treatments. I’ve gone through sinus sprays. I’ve gone through all kinds of different things,” he said ...

Feb 04, 2019

A Vivaer® Nasal Airway Remodeling pivotal study was recently published in Laryngoscope Investigative Otolaryngology. The prospective, multi-center, non-randomized US Pivotal Study was conducted to evaluate the treatment of nasal airway obstruction using the Vivaer® System ...

Feb 01, 2019

A new procedure to fix patients’ breathing problems is being offered in Alabama. Around 20 million Americans have trouble breathing through their nose. Quick and easy fixes have been hard to find, until the Food and Drug Administration approved technology in 2017 that allows patients to breathe normally again without surgery. This comes as a relief for patients like Mike Lahurd, who said breathing has been an issue since 1992 ...

Jan 03, 2019

A Vivaer® Nasal Airway Remodeling study on nasal obstruction and snoring was published in the European Archives of Oto-Rhino-Laryngology. The article covered a prospective, non-randomized study using Vivaer® to treat nasal obstruction and snoring ...

Oct 08, 2018

Dr. Daron Smith of Cornerstone ENT visits the Charlotte Today show on WCNC to discuss the Vivaer® Nasal Airway Remodeling procedure ...

Aug 24, 2018

Tony Vanetti, a host at WHAS, has the Vivaer® Nasal Airway Remodeling procedure performed by Dr. Vasu Kakarlapudi of Advanced ENT and Allergy. Aerin Medical may provide links to third-party sites ...

Jul 31, 2018

Aerin Medical, Inc. (“Aerin”) announced that over 1,000 patients suffering from nasal obstruction have successfully received the Vivaer® Nasal Airway Remodeling treatment (“Vivaer®“) which uses patented non-invasive low temperature radio frequency technology to reshape nasal tissues ...

May 23, 2018

“From start to finish, the procedure wasn’t even half an hour, and that includes the numbing and the procedure,” Linda Wells said. “Once the healing was done, I was amazed at how much better I could breathe.” ...

Jan 09, 2018

Aerin Medical, Inc. (“Aerin”) announced that it has received regulatory clearance for its novel Vivaer® Non-Invasive Airway Remodeling System (“Vivaer®“), a product developed to enable Ear, Nose & Throat (“ENT”) physicians to treat nasal airway obstruction within their physician office without the need for incisions or implants ...